Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Monalizumab + cetuximab is active in advanced SCC of the head and neck

Cohen R et al. SITC 2018, Abstract 051

Publish date:: November 27, 2018

Key clinical point: Monalizumab + cetuximab is safe, active in recurrent or metastatic SCC of the head and neck.

Major finding: Overall response rate in 40 evaluable patients was 27.5%,with 1 CR and 10 PRs at 8 weeks.

Study details: A cohort expansion of 40 patients in the single-arm, non-randomized phase 1/2 study.

Disclosures: Dr. Cohen reported receiving consulting fees and/or research funding from Cantargia, Celldex, Genocea, Innate, HEAT, Kyntherapeutics, Merck, Takeda Macrogenics, and Tmunity.

Read the article here.

Citation:

Cohen R et al. SITC 2018, Abstract 051.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Head & Neck/Thyroid Cancers

Immunotherapy could fill unmet need in leptomeningeal metastases,

New cancer drugs may have saved more than 1.2 million Americans,

‘Tour de force’ study reveals therapeutic targets in 38% of cancer patients,

Survey quantifies COVID-19’s impact on oncology,

VTE, sepsis risk increased among COVID-19 patients with cancer,